Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic nitric oxide synthase inhibition

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 1, 2005, Pages 25-35

  Tofovic, Stevan P ^a   Salah, Eman M ^b   Dubey, Raghvendra K ^a   Melhem, Mona F ^b   Jackson, Edwin K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Chronic renal failure; Estradiol; Metabolites

Indexed keywords

2 HYDROXYESTRADIOL; 2 METHOXYESTRADIOL; COLLAGEN TYPE 4; DRUG METABOLITE; ESTRADIOL DERIVATIVE; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHRONIC DRUG ADMINISTRATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENZYME INHIBITION; ESTROGEN ACTIVITY; GLOMERULUS; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HYPERTENSION; IN VIVO STUDY; INFLAMMATION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY TUBULE; MALE; MORTALITY; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANTIGEN-PRESENTING CELLS; BODY WEIGHT; CARDIOVASCULAR DISEASES; CREATININE; ENZYME INHIBITORS; ESTRADIOL; GLOMERULAR FILTRATION RATE; HEART; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; NITRIC OXIDE SYNTHASE; NITROARGININE; PROTEINURIA; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RENAL CIRCULATION; TIME FACTORS;

EID: 21444459241     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000162765.89437.ae     Document Type: Article

References (49)

1. Lindner A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697-701.
2. Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis. 2002;36:S24-S30.
3. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17(Suppl 1):29-36.
4. Neugarten J, Acharya A, Silbiger SR. Effects of gender on the progression of non-diabetic renal disease: A meta-analysis. J Am Soc Nephrol. 2000; 11:319-329.
5. Reckelhoff JF, Graner JP. Role of androgens in mediating hypertension and renal injury. Clin Exp Pharmacol Physiol. 1999;26:127-131.
6. Baylis C. Age-dependent glomerular damages in the rat: Dissociation between glomerular injury and both glomerular hypertension and hypertrophy. Male gender as a primary risk factor. J Clin Invest. 1994; 94:1823-1829.
7. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis. 1995;25:515-533.
8. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
9. Grady D, Herrington D, Bittner V, et al. HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
10. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of esrrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
11. Tofovic SP, Kusaka H, Kost CK, et al. Renal function and structure in diabetic, hypertensive, obese ZDF X SHHF-hybrid rats. Ren Fail. 2000; 22:387-406.
12. Tofovic SP, Jackson EK. Rat models of the metabolic syndrome. Methods Mol Med. 2003;86:29-46.
13. Tofovic SP, Dubey R, Jackson EK. 2-Hydroxyestradiol attenuates the development of obesity, the metabolic syndrome and vascular and renal dysfunction in obese ZSF1 rats. J Pharmacol Exp Ther. 2001;299: 973-977.
14. Tofovic SP, Dubey R, Jackson EK. Renoprotective effects of 2-hydroxyestradiol. J Am Soc Nephrol. 2001;12:86.
15. Tofovic SP, Dubey R, Salah ME, et al. 2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol 2002;13:2737-2747.
16. Martucci CP. Metabolic fate of catechol estrogens. In Merriam G, Lipsett MB, eds. Catechol Estrogens. New York: Raven Press, 1983:115-122.
17. Ball P, Emons G, Kayser H, et al. Metabolic clearance rates of catechol estrogens in rats. Endocrinology. 1983;113:1781-1783.
18. Zacharia LC, Piche CA, Fielding RM, et al. 2-hydroxyestradiol is a prodrug of 2-methoxyestradiol. J Pharmacol Exp Ther. 2004;309: 1093-1097.
19. Verhagen AM, Braam B, Boer P, et al. Losartan-sensitive renal damage caused by chroninc NOS inhibition does not involve increased renal angiotensin II concentrations. Kidney Int. 1999;56:222-231.
20. Verhagen AM, Hohbach J, Joles JA, et al. Unchanged cardiac angiotensin II levels accompany lorsatan-sensitive cardiac injury due to nitric oxide synthase inhibition. Eur J Pharmacol. 2000;400:239-247.
21. Shwaery GT, Vita JA, Keaney JF Jr. Antioxidant protection of LDL by physiological concentrations of 17(beta)-estradiol: requirement for estradiol modification. Circulation. 1997;95:1378-1385.
22. Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett. 1987;210:37-39.
23. Liehr JG. Antioxidant and prooxidant properties of estrogens. J Lab Clin Med. 1996;28:344-355.
24. Gallagher PE, Li P, Lenhart JR, et al. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension. 1999;33:325-328.
25. Nickenig G, Baumer AT, Grohe C, et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation. 1998;97:2197-2201.
26. Rosenfeld CR, Jackson GM. Estrogen-induced refractoriness to the pressor effects of infused angiotensin II. Am J Obstet Gynecol. 1984;148: 429-435.
27. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int. 1999;55:278-285.
28. 2+ mobilization. Circ Res. 1997;81:885-892.
29. Chang WC, Nakako J, Orimo H, et al. Stimulation of prostaglandin cycloxygenase and prostacyclin synthase activities by estradiol in aortic smooth muscle cells. Biochim Biophys Acta. 1980;620:472-482.
30. Ylikorkala O, Orpana A, Puolakka J, et al. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab. 1995;80:3384-3387.
31. Silbiger S, Lei J, Ziyadeh FN, et al. Estradiol reverses TGF-β1 stimulated type IV collagen gene transcription in murine mesangial cells. Am J Physiol Renal Physiol. 1988;274:F1113-F1118.
32. Neugarten J, Jei J, Acharya S, et al. Estradiol reverses angiotensin II- and endothelin-simulated mesangial cells COLA41 gene transcription by antagonizing autocrine TGFβ1. J Am Soc Nephrol. 1999;10:577A. (Abstract)
33. Potier M, Elliot SJ, Tack I, et al. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase 9. J Am Soc Nephrol. 2000;112:241-251.
34. Morey AK, Razandi M, Pedram A, et al. Oestrogen and progesterone inhibit the stimulated production of endothelin-1. Biochem J. 1998;330: 1097-1105.
35. Dubey RK, Jackson EK, Keller PJ, et al. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension. 2001;37:640-644.
36. Neugarten J, Ghossein C, Silbiger S. Estradiol inhibits mesangial cell mediated oxidation of low-density lipoprotein. J Lab Clin Med. 1995;126: 385-391.
37. Dubey RK, Tyurina YY, Tyurina VA, et al. Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ Res. 1999;84:229-239.
38. Tofovic SP, Muddy H, Jackson EK. Estradiol attenuates cardiovascular and renal injury induced by chronic Angiotensin II administration in rats. Hypertension. 2003;42:416 (Abstract).
39. Tofovic SP, Jackson EK, Muddy H. 2-Methoxyestradiol attenuates cardiovascular remodeling in constricted aorta rat model. J Am Soc Nephrol. 2003;14:620.
40. Verhagen AM, Rabelink TJ, Braam B, et al. Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition. J Am Soc Nephrol. 1998;9: 755-762.
41. Attia DM, Verhagen AM, Stroes ES, et al. Vitamin E alleviates renal injury, but not hypertension, during chronic nitric oxide synthase inhibition in rats. J Am Soc Nephrol. 2000;12:2585-2593.
42. Lipsett MB, Merriam GR, Kono S, et al. Metabolic clearance of catechol estrogens. In Merriam G, Lipsett MB, eds. Catechol Estrogens. New York: Raven Press, 1983:105-114.
43. Zanchi A, Schaad NC, Osterheld MC, et al. Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol. 1995;268:H2267-H2273.
44. Zaharia CL, Jackson EK, Gillespie DG, et al. Catecholamines block 2-hydroxyestradiol-induced antimitogenesis in mesangial cells. Hypertension. 2002;39:854-859.
45. Zacharia LC, Dubey RK, Mi Z, et al. Methylation of 2-hydroxyestardiol in isolated organs. Hypertension. 2003;42:82-87.
46. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther. 2004;309:403-409.
47. 125I-labeled ligand. Acta Endocrinol. 1983;103:282-288.
48. Ball P, Knuppen R. Formation, metabolism, and physiological importance of catechol estrogens. Am J Obstet Gynecol. 1990;163:2163-2170.
49. Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol. 2001;127:405-410.